Journal article

Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice

Cynthia PW Soon, Peter J Crouch, Bradley J Turner, Catriona A McLean, Katrina M Laughton, Julie D Atkin, Colin L Masters, Anthony R White, Qiao-Xin Li

Neuromuscular Disorders | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2010

DOI: 10.1016/j.nmd.2009.11.015

Grants

Awarded by NHMRC

Awarded by CJ Martin Fellowship

Funding Acknowledgements

We thank Dr. Su San Mok for comments. This work was supported in part by NHMRC program Grant #400202, CJ Martin Fellowship #359269 (BJT), the Bethlehem Griffiths Research Foundation, and the Motor Neurone Disease Research Institute of Australia.

Citation metrics

15Web of Science
18Scopus

Keywords

Mutation
Mechanisms
Gene Expression Regulation, Enzymologic
Neurosciences & Neurology
Matrix Metalloproteinase-2 (mmp-2)
Disease Models, Animal
Motor-Neuron Degeneration
Mice, Transgenic
Amyotrophic Lateral Sclerosis
Serum
Genetic Predisposition To Disease
Superoxide Dismutase
Mice
Biomarkers
Zymography
Disease Progression
Aggregation
Animals
Neuroglia
Superoxide Dismutase-1
Clinical Neurology
Matrix Metalloproteinase 9
Mouse Model
Expression
Gene Dosage
Familial Als
Matrix Metalloproteinase 2
Spinal Cord
Matrix Metalloproteinase-9 (mmp-9)
Amyotrophic Lateral Sclerosis (als)
Amyotrophic-Lateral-Sclerosis
Superoxide Dismutase 1 (sod1)
Motor Neurons
Life Sciences & Biomedicine
Science & Technology
Inhibitors
Spinal-Cord
Neurosciences
Sod1g93a Transgenic Mice
Matrix Metalloproteinases Mmp-2